Barrett’s Esophagus Test Identifies High-Risk Patients Missed by Standard Pathology
A study of 85 patients shows the TissueCypher test detected 15% with elevated cancer progression risk despite a non-dysplastic diagnosis.
Category: Uncategorized
Uncategorized
Latest
Uncategorized
Latest
Color Health Partners with CDC to Increase Access to COVID Testing
Color Health is providing free COVID testing through the CDC's Increasing Community Access to Testing program.
Uncategorized
Latest
Ortho Clinical Diagnostics, Thermo Fisher Scientific Partner on QC Solutions
Ortho Clinical Diagnostics has a distribution agreement with Thermo Fisher Scientific to provide and support MAS Quality Controls and LabLink xL Quality Assurance Software through Ortho's Vitros QC Solutions to Vitros System customers worldwide.
Clinical Chemistry
Latest
Quest Diagnostics to Integrate 50-Biomarker Test Panel into Apple Health App
Quest Diagnostics will integrate a 50-biomarker lab test panel into the Apple Health app, allowing US users to order preventive testing and access clinical results on iPhone and iPad.
Flow Cytometry
Latest
Hematogenix MRD Assay Supports FDA Approval of Multiple Myeloma Therapy
Hematogenix’s next-generation flow cytometry assay was used as the pivotal efficacy measure supporting FDA accelerated approval of ZENBEXUS, the first CELMoD therapy for multiple myeloma.
Mass Spectrometry
Latest
Pillar Biosciences and Hamilton Launch Automated NGS Library Prep for 21-Gene Panel
Pillar Biosciences and Hamilton Company have launched an automated NGS library prep method for the oncoReveal Nexus 21 Gene Panel, validated for use on Hamilton’s Microlab STAR and STARlet liquid handling systems.
Immunoassay
Latest
Health Canada Approves Blood-Based Neurology Assays for Lumipulse Platform
Health Canada has approved Fujirebio’s Lumipulse G NfL Blood and pTau 217 Plasma assays, expanding access to blood-based neurology biomarkers for clinical use on the Lumipulse G immunoassay platform.
Molecular Diagnostics
Latest
MolDX Proposes Medicare Coverage for Optical Genome Mapping in Hematologic Neoplasms
MolDX has proposed a draft Local Coverage Determination to establish Medicare coverage criteria for optical genome mapping in hematologic neoplasms, with public comment open through Oct. 11, 2026, according to Bionano Laboratories.
Point-of-Care
Latest
Roche Receives FDA Clearance for Point-of-Care Bordetella Test
The cobas liat system delivers PCR results in 15 minutes, detecting and differentiating between three Bordetella pathogens including whooping cough.